马波沙星注射液的研制

《马波沙星注射液的研制》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号12185HebeiMedicalUniversity硕士学位论文在职科学学位马波沙星注射液的研制学位申请人：刘毅导师：曹德英教授专业：药剂学二级学院：药学院2015年3月河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师(或指导小组)的指导下，由本人独立完成。本学位论文研究所获得的研究成果,其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用。凡发表与学位论文主要内容相关的论文,第一署名为单位河北医科大学，试验材料、原始数据、申报的专利等知识产权均归河北医科大学所有。否则,承担相应法律责任。

2、研究生签名^导师签章二级学院领导盖章-年月日河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加以标注和致谢等内容外，文中不包含其他人已经发表或撰写的研究成果,指导教师对此进行了审定。本论文由本人独立撰写,文责自负。研究生签名:来^导师签章年月日目录中文摘要·············································································1英文摘要·················································

3、····························3英文缩写·············································································6研究论文马波沙星注射液的研究前言·············································································7第一部分马波沙星注射液的制备材料与方法·····························································

4、·······9结果·············································································10讨论·············································································11第二部分马波沙星注射液的质量研究材料与方法····································································12结果······················

5、·······················································16讨论·············································································18附图·············································································19附表································································

6、·············26第三部分马波沙星注射液的稳定性研究材料与方法····································································28结果·············································································29讨论·············································································29附表··············

7、·······························································30第四部分马波沙星注射液的药代动力学研究材料与方法····································································32结果·············································································35讨论···········································

8、·····